Skip to main content

Short Reads: May 1, 2002


Lion Bioscience announces that Martin Hollenhorst has been appointed to CFO, previously held by Klaus Sprockamp, who was killed in New York City on September 11.


Braving the wake of Alex Titomirov, Andrew Whiteley heads to InforMax as chairman, CEO, and president. He was previously bioinformatics veep at Amersham.


Jim Golden uproots from his post as bioinformatics director at CuraGen for a new position as business development manager at its notoriously off-radar subsidiary 454. Lifetime GT subscription for anyone who buys Golden a gimlet and gets him to spill the dirt on what 454’s doing.


AnVil, which recently took the wild and crazy step of dropping “Informatics” from its name and then milked the move as a major PR opportunity, also announced the hiring of John Hallinan as CFO and John McCarthy as director of discovery informatics. (Or is that just discovery now?)


GenStruct, a new informatics-oriented discovery company in Cambridge, Mass., appoints Jeffrey Thomas as CSO and Navin Chandra as CTO. Thomas hails from the genomics and bioinformatics division at Pfizer, and Chandra comes from his own startup, NovaSpike.

Exelixis takes steps to augment its discovery and development side with the hires of Kimberly Manhard, vice president of regulatory affairs; Harold Keer, director of clinical R&D; and Annie Fong, director of development.


Former NetGenics employee and self-professed serial CEO Richard Resnick is interim chief exec of systems biology company GeneGo.


Michael Nemzek, who was most recently CBO at Cellomics, becomes executive veep of business development at Aspira Biosystems.


Speaking of business development, Aviva Biosciences chose former Incyte VP Eric Lachenmeier as its new director of biz dev.


Still speaking of business development (is anyone else noticing a pattern here?), Philip Sussman goes to Perlegen Sciences as BD VP. Though Sussman appears to have no experience in making films, he did work for biotech firms SIGA Technologies, Memory Pharmaceuticals, and Cadus Pharmaceutical.


Will Venter and Lander stop vying for the Nobel Prize? Perhaps, if getting to the Oscars counts as an equal honor. That sure looked like Eric Lander stumping for Mary Poppins on the Academy Awards Hollywood lovefest. Eric, can we have your autograph?

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.